On Invalid Date, Aerovate Therapeutics (NASDAQ: AVTE) reported Q4 2023 earnings per share (EPS) of -$0.74, up 21.31% year over year. Total Aerovate Therapeutics earnings for the quarter were -$20.41 million. In the same quarter last year, Aerovate Therapeutics's earnings per share (EPS) was -$0.61.
As of Q2 2024, Aerovate Therapeutics's earnings has grown year over year. Aerovate Therapeutics's earnings in the past year totalled -$75.52 million.
What is AVTE's earnings date?
Aerovate Therapeutics's earnings date is Invalid Date. Add AVTE to your watchlist to be reminded of AVTE's next earnings announcement.
What was AVTE's revenue last quarter?
On Invalid Date, Aerovate Therapeutics (NASDAQ: AVTE) reported Q4 2023 revenue of $0.00 up N/A year over year. In the same quarter last year, Aerovate Therapeutics's revenue was $0.00.
What was AVTE's revenue growth in the past year?
As of Q2 2024, Aerovate Therapeutics's revenue has grown null year over year. Aerovate Therapeutics's revenue in the past year totalled $0.00.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.